The nuclear hormone receptor estrogen receptor a (ERa) promotes cellular growth through liganddependent activation of specific target genes, a process which is targeted in the treatment of ERaexpressing breast cancers. ERa activity is regulated at the protein level by post-translational modifications including phosphorylation and acetylation. A study now shows that ERa can also be directly methylated at lysine 302 (K302) by SET7, a histone methyltransferase that is known to monomethylate H3K4 and is associated with transcriptional activation. It was shown that K302 methylation stabilizes ERa protein and is suggested to increase sensitivity of ERa to estrogens, enhancing transcription of estrogen response elements. Furthermore, SET7 methylation of K302 is enhanced by a breast cancer-associated mutation at K303 (K303R) in vitro. These findings provide an additional mechanism of SET7 mediated transcriptional activation, as well as potential insight into the complex regulation of ERa stability and ligand sensitivity.
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Estrogens such as 17b-estradiol (E 2 ) are synthesized predominantly in ovaries or via aromatization in peripheral tissues and play a pivotal role in the development of breast, ovarian, and endometrial cancers (Yager & Davidson 2006) . The role of ER, particularly ERa, and its ligands in breast carcinogenesis has been recognized for some time (Yager & Davidson 2006) . Indeed, about 70% of newly diagnosed invasive breast cancers express ERa protein and this expression identifies cancers that are potentially amenable to endocrine approaches designed to deplete ligand or receptor, or impede ligand-receptor interactions. Although other important factors affecting endocrine therapies have come to light in recent years (e.g. HER-2 expression and progesterone receptor status), molecular studies have indicated that ERa-related pathways are a major determinant of endocrine responsiveness (Rastelli & Crispino 2008) .
Much work has focused on mechanisms that regulate ERa expression in human breast cancer cells. It has been hypothesized that epigenetic mechanisms including DNA methylation and/or histone modifications might contribute to silencing of ERa expression (Ottaviano et al. 1994 , Leader et al. 2006 . Indeed, several studies have demonstrated that the ERa CpG island is hypermethylated in ERa-negative human breast cancer cells and treatment of these cells with inhibitors of DNA methyltransferases such as 5-azacitidine or decitabine elicits reexpression of functional ERa protein. Furthermore, covalent histone modifications, such as the methylation or acetylation of lysine residues, can also contribute to the transcriptional silencing or activation of ERa (Sharma et al. 2006 , Macaluso et al. 2007 . Site-specific modifications in the N-terminal tail region of core and linker histones specify a histone code of epigenetic regulation that dictates a specific active or inactive chromatin state (Strahl & Allis 2000) . Methylation of lysine residues can occur on histones H3 and H4, thereby contributing to a chromatin conformation compatible with either active or repressed gene transcription, depending on the residue modified and the degree of methylation (Sims et al. 2003) . In particular, monomethylation at histone H3 lysine 4 (H3K4Me1) is associated with transcriptionally competent euchromatin (Noma et al. 2001) , but the mechanism of H3K4Me1associated transcriptional activation is poorly understood.
Several histone H3K4-specific methyltransferases have been identified including human SET7 (also known as SET9; Wang et al. 2001b) . The suppressor of variegation, enhancer of zeste and trithorax (SET) domain is an evolutionarily conserved sequence motif originally described in Drosophila; it is present in chromosomal proteins that function in epigenetic control of gene expression (Jenuwein et al. 1998) . Early studies revealed that SET7 activates transcription by preventing chromatin condensation (Wang et al. 2001b , Nishioka et al. 2002 . Importantly, SET7 can methylate specific lysines on non-histone proteins including transcriptional factors and regulators like p53 and TAF10. SET7 methylation stabilizes and inhibits nuclear export of p53, leading to the transcriptional activation of the p53 target genes (Chuikov et al. 2004) . Likewise, SET7 methylation has a stimulatory effect on TAF10 mediated transcription by increasing TAF10 affinity for interaction with RNA polymerase II (Kouskouti et al. 2004) . These studies suggest that the role of SET7 methylation in transcriptional activation reaches beyond the modification of histones.
Another such non-histone target appears to be ERa. Evidence has been emerging that lysine residues in the ERa hinge region can be targets for multiple types of posttranslational modifications (PTMs) including acetylation, phosphorylation, and ubiquitination ( Fig. 1) . These modifications may affect hormone sensitivity through alteration of ERa stability or regulation of estrogen-dependent gene transcription. Histone acetyltransferases such as p300 and histone deacetylase inhibitors have been shown to induce acetylation at several lysines within the hinge region. Coactivator-dependent acetylation of K266 and K268 by p300 increases ERa transcriptional activity by enhancing DNA binding (Kim et al. 2006) , whereas acetylation of K303 may attenuate hormone sensitivity through dissociation of transcriptional coactivators from the promoter (Wang et al. 2001a) . Studies have found that hyperphosphorylation of serine at 305 (S305) enhances estrogen-induced transcriptional activity and acetylation of lysine at 303 inhibits S305 phosphorylation (Cui et al. 2004) . Other covalent modifications such as ubiquitination at K302 (Berry et al. 2008 ) and sumoylation at K266 and K268 (Sentis et al. 2005) have also been shown to affect estrogen receptor stability and activity. Together, these data suggest that the complex cellular responses to E 2 are significantly affected by PTMs. However, it was not clear how ERa methylation might play a role in estrogen signaling until Subramanian and colleagues recently presented the first evidence that ERa is regulated by the SET7 lysine methyltransferase in human breast cancer cells (Subramanian et al. 2008) . In fact, this is only the second account in the literature of regulation of a nuclear receptor by direct methylation, shortly following the discovery that retinoic acid receptor a activity is regulated by lysine trimethylation (Huq et al. 2007) .
Using an in vitro methylation assay of peptide substrates (ERa, androgen receptor (AR), glucocorticoid receptor (GR) and mutant ERa), and recombinant purified HMTases, they found that the methylation of lysine in the ERa hinge region is specifically targeted by SET7. Through mass spectrometric analysis, they identified K302 as the only site of methylation by SET7 within the ERa hinge region in vitro. To confirm these findings in vivo, the authors raised a specific antibody against an ERa peptide that is monomethylated at K302; its specificity and sensitivity for this methylated residue were convincingly demonstrated by dot-blot analysis. They then transiently transfected ERa-negative HeLa cells with expression constructs for SET7 and ERa, and cell lysates were immunoprecipitated for ERa, followed by western blot analysis. Their findings demonstrate that ERa is methylated at K302 by SET7 in cell culture and that this methylation can be decreased by mutation of K303 to arginine (K303R). This latter observation is of particular interest because an acquired missense mutation in the ERa gene resulting in K303R substitution has been reported in primary breast ductal hyperplasia and cancers from patients in the southern USA (Fuqua et al. 2000 , Conway et al. 2005 but not in Japan or the UK (Tokunaga et al. 2004 , Davies et al. 2005 . These studies lead to the conclusion that SET7 serves as a specific HMTase to monomethylate K302 and SET7-mediated methylation of K302 may be altered by the mutation of the neighboring K303. The structural basis of these findings was elaborated with high-resolution X-ray data from co-crystals of full length SET7 protein with an ERa peptide. The series of structures representing the phases of turnover in ERa methylation show a salt bridge between ERa N304 and SET7 K317, which is indicative of enhanced SET7 binding (Couture et al. 2006) and another between ERa K303 and SET7 D338, consistent with the in vitro and in vivo observations. A limitation of these studies is that Subramanian et al (2008) were unable to detect methylation of endogenous ERa in MCF-7 cells, possibly due to celltypespecific dysregulation of ERa modification. It is also unfortunate that they did not extend any of these studies to other ERa-positive human breast cancer cells to determine how general the findings might be.
The role of SET7-mediated methylation in the regulation of ERa function was carefully addressed by the authors. They stably transfected retroviral vectors that contained SET7 shRNA into the ERa-positive MCF-7 breast cancer cell line to generate shSET7 knockdown cells. Results show that knockdown of SET7 concomitantly decreases the steadystate levels of ERa protein but not ERa mRNA, suggesting that methylation of K302 by SET7 modulates ERa protein stability. Pulse chase experiments confirmed that ERa halflife is decreased by about twofold in shSET7 cells compared with control cells. Consistent with these observations, estrogen response elements (ERE)-coupled luciferase reporter assays showed that estrogen-driven transcription is dramatically inhibited in shSET7 knockdown clones. Further estrogen-induced transactivation of two classic endogenous ERa target genes, PS2 and PgR, was blunted in shSET7 cells, suggesting that SET7 is required for estrogen-induced transcriptional response. One potential mechanism of SET7 mediated enhancement of ERE transcription is through alteration of protein binding complexes in the ERa target gene promoters. Therefore, the authors used quantitative chromatin immunoprecipitation (ChIP) assays to determine that SET7 regulates ERa target genes by altering ERa binding to target gene regulatory sequences. Furthermore, they established that ERa and NCoA2 but not SET7 act as coactivators at the PS2 gene promoter in multiple cell lines. However, this does not preclude the possibility that SET7 could act on ER co-factors in addition to ERa, a matter that will not be resolved until the non-histone targets of SET7 are extensively studied.
This study by Subramanian and colleagues has substantially enhanced our knowledge of the role of PTMs of ERa hinge region in the estrogen-dependent gene transcription pathway. Also, the stabilization of ERa by SET7 provides additional complexity to a new-found dimension of the epigenetic code, whereby specific PTMs of transcription Endocrine-Related Cancer (2009) 16 319-323 www.endocrinology-journals.org factors could make a significant contribution to the transcriptional activity commonly attributed to a specific histone modification (Fig. 2) . These findings raise important questions, some relevant to the field of epigenomics as well as molecular endocrinology. First, to what extent is the SET7 induced upregulation of ERE transcription responsible for the transcriptional activation-associated with concordant H3K4 monomethylation in ERa-expressing tissues? Also, what of the reverse? Does SET7 activity play a role in ERadependent proliferation of breast cancer, or resistance to endocrine therapies? The answers to these questions could determine the potential of SET7 as a target for breast, or other endocrine-related cancers. Also, as noted earlier, extension of these studies to other cell lines is extremely important to show, whether the findings are general and to understand what other cell-type factors might play a role. Indeed, other studies have shown that, in addition to nuclear gene transcription, ERa carries out various cellular functions at the plasma membrane and the mitochondria in a celltypespecific manner (Zhang et al. 2002 , Pedram et al. 2006 . It is quite plausible that the cellular localization and function of ERa is regulated by specific PTMs as well.
This study is one of several suggesting that PTMs of ERa may play a role in hormone response. Methylation of K302 is of particular interest in view of reports that the functional consequences may be of substantial impact and may be modulated by the adjacent K303R variant that has been reported in human breast cancers, especially those with more aggressive clinical features and poorer prognosis. Thus, these findings may ultimately lead to the development of new anticancer therapies that specifically manipulate SET7 and alter estrogen-signaling pathways.
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